Moderna and Merck report that a new mRNA anti-cancer vaccine under investigation used in combination with standard therapy to treat stage IV melanoma reduces risk of relapse compared to standard therapy alone.

Medical Mythbusting Commentary for December 14, 2022

Experimental mRNA cancer vaccine with immunotherapy reduces risk of melanoma returning, preliminary study finds


Awaiting data release and publication